SciELO - Scientific Electronic Library Online

vol.32 issue5Fibroblast growth factor 23 (FGF 23) and phosphocalcic metabolism in chronic kidney diseaseOutcomes weighting for comprehensive haemodialysis centre assessment author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google


Nefrología (Madrid)

On-line version ISSN 1989-2284Print version ISSN 0211-6995


ARROYO, David et al. Hypercalcaemia as a side effect of potassium binding agents. Nefrología (Madr.) [online]. 2012, vol.32, n.5, pp.655-658. ISSN 1989-2284.

Hypercalcaemia is a potential adverse effect of calcium-containing ion exchange resins, often used in the treatment and prevention of hyperkalaemia in chronic kidney disease (CKD). We describe a series of seven outpatients with moderate CKD (mean glomerular filtration rate estimated with the CKD-EPI formula: 41.29±10.83mL/min/1.73m2), presenting mild hypercalcaemia in relation to the treatment with calcium polystyrene sulfonate. Serum calcium increased a mean of 0.91±0.46mg/dL, with a mean concomitant decrease of serum intact parathormone (iPTH) of 52.24±49.29ng/dL. After treatment withdrawal or dose reduction, we observed a recovery of serum calcium and iPTH values. Treatment with calcium-based potassium binders should be included in the differential diagnosis of hypercalcaemia in patients with moderate CKD.

Keywords : Ion exchange resins; Hypercalcaemia; Hyperpotassemia; Polystyrene sulfonate calcium.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License